StreetAlpha.app
Home › Stocks › SEPN

Septerna, Inc. (SEPN)

Healthcare
$40.02
▼ −3.96%
LAST CLOSE · NOV 17

Septerna is a clinical stage biotech company developing oral small molecule medicines that target G protein coupled receptors. It last closed at $40.02 on Nov 17, down 3.96% on the day. The average 12-month price target from 3 analysts is $62.00 (+54.9% from the last close), with a high of $65.00 and a low of $60.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $805K, the largest $805K.

AI Auto Pilots
Is SEPN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$96.3M
+336.7% vs a year ago
Net income
−$59.0M
−61.3% margin
EPS (diluted)
−$1.30
−109.5% vs a year ago
Free cash flow
−$77.6M
−80.6% margin
Valuation
Market cap
$1.9B
47.5M shares
P/E
–
No P/E while losing money
Price to sales
19.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$167.1M
At Sep 30
Shareholder equity
$427.9M
Shares outstanding
47.5M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $151K$151KFY2023FY2024: $1.1M$1.1MFY2024FY2025: $46.0M$46.0MFY2025

From SEPN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on SEPN in the past 90 days
Average 12-month target
$62.00
▲ 54.9% upside

Based on 3 analysts who set a price target on SEPN in the past 90 days. The average target is $62.00, with a high of $65.00 and a low of $60.00, compared with the last close of $40.02.

Low $60.00Avg $62.00High $65.00
Blue marker: last close $40.02
Highest target$65.00
Average target$62.00
Lowest target$60.00
Latest rating changes
StifelMaintained
Nov 10Buy$60
GuggenheimTarget raised
Nov 6Buy$51 → $65
Wells FargoTarget raised
Nov 4Buy$50 → $61
JP MorganMaintained
Aug 19Buy$48
Jones TradingMaintained
Aug 13Buy$62
DateFirmActionRatingPrice target
Nov 10StifelMaintainedBuy$60
Nov 6GuggenheimTarget raisedBuy$51 → $65
Nov 4Wells FargoTarget raisedBuy$50 → $61
Aug 19JP MorganMaintainedBuy$48
Aug 13Jones TradingMaintainedBuy$62
Loading…

Technical Analysis

SEPN · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 11% below its 20 day and 1% below its 50 day average. It is 17% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the 100 day average at $39.06, and the nearest resistance the Pivot at $40.32.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 8.0%/day
Key levels
$53.3452 week high+33.3%
$44.4920 day average+11.2%
$41.37Pivot R1+3.4%
$41.09Swing high (Sep 22)+2.7%
$40.6250 day average+1.5%
$40.32Pivot+0.7%
$40.02Last close
$39.06100 day average−2.4%
$38.98Pivot S1−2.6%
$38.96Swing low (Aug 24)−2.6%
$33.29200 day average−16.8%
$21.3152 week low−46.8%
Indicators
RSI (14)42.78Middle of its rangeNeutral
MACD0.96Below its signal lineBearish
Stochastic8.7Near the bottom of its rangeOversold
ADX (14)16.5No clear trend
Williams %R-94.7Oversold below −80, overbought above −20Oversold
CCI (20)-95.5Oversold below −100, overbought above 100Neutral
Rate of change−8.4%Change over 10 sessionsBearish
ATR (14)$3.20Typical daily range, 8.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for SEPN

What happened before

See how SEPN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in SEPN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$805K
Largest print
$805K
Loading…

SEPN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲111 buying vs 54 selling
  • ▲Held by funds +3.8 pts
  • ▲Funds holding +17
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding173156+10.9%
In funds' top 1084+100.0%
Held by funds103.6%99.8%+3.8 pts
New / increased32 / 7946 / 49+16.8%
Reduced / sold out38 / 1632 / 16+12.5%
Put/call ratio0.740.56+30.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SEPN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SEPN is in one of them and how their past SEPN trades turned out.

SEPN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SEPN in an article yet. Here's the latest on the wider market.

About Septerna

Septerna is a clinical stage biotechnology company based in South San Francisco, California. It uses its Native Complex Platform to discover oral small molecule medicines that act on G protein coupled receptors, a large family of proteins that help control many processes in the body. Its pipeline is focused on endocrine diseases, immune and inflammatory conditions, and metabolic diseases. The company aims to develop these medicines for patients with significant unmet medical needs.

Headquarters
South San Francisco, CA